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Abstract: Risk of celiac disease (CD) is increased in relatives of CD patients due to genetic and possible
environmental factors. We recently reported increased seropositivity to anti-Saccharomyces cerevisiae
(ASCA), Pseudomonas fluorescens-associated sequence (anti-I2) and Bacteroides caccae TonB-linked
outer membrane protein (anti-OmpW) antibodies in CD. We hypothesized these markers also to
be overrepresented in relatives. Seropositivity and levels of ASCA, anti-I2 and anti-OmpW were
compared between 463 first-degree relatives, 58 untreated and 55 treated CD patients, and 80 controls.
CD-associated human leukocyte antigen (HLA)-haplotypes and transglutaminase (tTGab) and
endomysium (EmA) antibodies were determined. One or more of the microbial antibodies was
present in 75% of relatives, 97% of untreated and 87% of treated CD patients and 44% of the controls.
The relatives had higher median ASCA IgA (9.13 vs. 4.50 U/mL, p < 0.001), ASCA IgG (8.91 vs.
5.75 U/mL, p < 0.001) and anti-I2 (absorbance 0.74 vs. 0.32, p < 0.001) levels than controls. There was
a weak, positive correlation between tTGab and ASCA (r = 0.31, p < 0.001). Seropositivity was
not significantly associated with HLA. To conclude, seropositivity to microbial markers was more
common and ASCA and anti-I2 levels higher in relatives of CD patients than controls. These findings
were not associated with HLA, suggesting the role of other genetic and environmental factors.
Keywords: celiac disease; relatives; microbiota; Saccharomyces cerevisiae; Pseudomonas fluorescens;
Bacteroides caccae
1. Introduction
Celiac disease (CD) is an immune-mediated condition characterized by gluten-induced
small-bowel enteropathy. Almost all patients carry human leukocyte antigen (HLA) alleles encoding
DQ2 or DQ8 heterodimers [1]. These alleles are nevertheless also present in up to 35% of the general
population and do not fully explain the genetic risk [2]. Recent genome-wide association studies and
immunogenetic studies have identified numerous non-HLA loci and single nucleotide polymorphisms
that may modify CD risk [3,4]. Partly due to shared genetic predisposition, the relatives of patients
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have an increased susceptibility to CD, the average prevalence among first-degree relatives being
approximately 8% [5] compared with 1%–2% in the general population [6,7].
However, only a minority of at-risk individuals develop CD, and the concordance even varies
between identical twins [8,9], which implicates environmental factors. The prevalence may also
vary between adjacent countries with similar genetic backgrounds and gluten consumption [10],
and retrospective measurements of stored samples indicate a rise in the true incidence [6,11,12].
As one potentially associated factor, the role of intestinal microbiota in the development of CD has
aroused particular interest [13–15]. Previously, we and others observed elevated levels of antibodies
to microbial markers Saccharomyces cerevisiae (ASCA), Pseudomonas fluorescens-associated sequence
(anti-I2) and Bacteroides caccae TonB-linked outer membrane protein (anti-OmpW) in inflammatory
bowel disease [16–18]. We have shown increased seroreactivity to these markers also in overt CD [19]
and a decrease of the antibody levels during gluten-free diet (GFD) [20]. Further, these microbial
markers are detectable in early stages of the disease even before the presence of villous atrophy and
serum CD-specific autoantibodies [21].
We hypothesized that close relatives of CD patients, with partially shared living environments
and genetic factors, could have increased seroreactivity to microbial markers. This was investigated by
comparing their frequency of seropositivity and levels of microbial antibodies with those in untreated
and treated CD patients and in healthy controls.
2. Materials and Methods
2.1. Study Participants
The study was carried out at Tampere University and Tampere University Hospital. Previously
diagnosed CD patients were recruited in a nationwide search through newspaper advertisements
and via patient societies. Their medical records were obtained with permission, and only subjects
with a biopsy-proven diagnosis were included. Relatives of these patients were invited to a screening
study comprising personal interviews and measurement of CD serology. Additional blood samples
were drawn for research purposes. Exclusion criteria for the relatives were previously diagnosed CD
or dermatitis herpetiformis, or otherwise initiated gluten-free diet (GFD). Altogether, 3031 relatives
met the inclusion criteria and entered the original screening study. Duodenal biopsy was offered for
all relatives with positive CD serology. For the present study, serum samples from 463 first-degree
relatives were randomly selected for the measurement of ASCA, anti-I2 and anti-OmpW. The CD
control group comprised 58 biopsy-proven patients who underwent measurements of the CD serology
and microbial markers at diagnosis and after one year on GFD (n = 55). In addition, 80 adult blood
donors with negative CD serology served as non-CD controls.
2.2. CD Autoantibodies and Genotyping
Serum immunoglobulin A (IgA) class endomysium autoantibodies (EmA) were tested by an
indirect immunofluorescence method using human umbilical cord as substrate [22]. Titers 1: ≥ 5 were
deemed positive and diluted up to 1:4000 or until negative. Serum IgA class tissue transglutaminase
autoantibodies (tTGab) were measured by an enzyme-linked immunosorbent assay (ELISA, INOVA
diagnostics, San Diego, CA) according to the manufacturer’s instructions. A cutoff ≥ 30 U/mL was
applied for seropositivity. Some of the CD autoantibody-positive relatives declined the biopsy, but,
due to the high specificity of EmA/tTGab [23], the vast majority of them are also likely to have CD.
They were therefore analyzed as a separate group.
The CD-associated HLA DQ haplotypes (DQ2.5, DQ2.2, DQ8) were determined from the relatives
and CD patients with the tagging single nucleotide polymorphism method or with the Olerup SSP DQ
low-resolution kit (Olerup SSP AB, Stockholm, Sweden) as described elsewhere [24,25].
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2.3. Microbial Antibodies
Serum IgA and IgG class ASCA were measured by a commercial ELISA (Quanta Lite ASCA,
INOVA Diagnostics Inc., San Diego, CA) considering levels ≥ 25 U/mL positive. E. coli XL-1 blue
and E. coli BL-21 (Stratagene, La Jolla, CA) strains and previously reported antigen purification
techniques [26,27] were used to produce I2-GST and OmpW antigens. The serum samples were diluted
1:50, and IgA anti-I2 and anti-OmpW antibodies were measured with an in-house ELISA. For anti-I2,
the cutoff level for positivity was set at absorbance 0.5. For anti-OmpW, it was set at 0.6 in children and
1.0 in adults based on our previous studies showing age differences in the normal range [16,19].
2.4. Statistical Analysis
Quantitative data are shown in tables as percentages or as medians with lower and upper quartiles.
The data were cross-tabulated in order to ascertain the overlap of seropositivity for microbial antibodies
in different study groups. The Kruskal–Wallis test was used to compare the differences in microbial
antibody levels between the groups. Correlations between autoantibodies and microbial markers were
tested with Spearman’s rank correlation coefficient. Associations in the seropositivity to microbial
antibodies within and between the families were also tested. The chi-square statistic for the change in
the -2 log-likelihood from the constant only model to the model with “family” was used to determine
whether the inclusion of “family” contributed significantly to model fit. A p value < 0.05 was considered
significant. Statistical analyses were carried out with SPSS Statistics for Windows (IBM Corp., Armonk,
NY, USA).
2.5. Ethical Aspects
The study protocol was approved by the Ethics Committee of the Pirkanmaa Hospital District,
study identification code ETL R05183. All participants or, in the case of children, their legal guardians
gave written informed consent. The paper follows the rules of the Declaration of Helsinki.
3. Results
The gender distribution was fairly equal among the relatives, whereas a majority of CD patients
were women, and there were more men in the non-CD control group (Table 1). There were no major
differences in the median ages between the groups (Table 1), but 49 (10.6%) of the relatives were
<18 years of age, while the other groups comprised only adults.











n = 49 n = 414 n = 58 n = 55 n = 80
Females, % 42.9 57.2 77.6 76.4 35.0
Age, median (quartiles), y 41 (31–54) 42 (28–59) 45 (36–59) 46 (38-60) 41 (31–56)
* Negative serum endomysium (titer 1: < 5) and tissue transglutaminase (< 30 U/mL) antibodies. GFD, gluten-free diet.
The relatives were divided into CD autoantibody-negative (n = 414) and autoantibody-positive
(n = 49) groups and were analyzed separately (Table 1). Among the autoantibody-negative relatives,
seropositivity for at least one of the microbial markers was more common than in the non-CD controls
but less frequent than in the CD patients (Figure 1). The most notable difference was seen in ASCA,
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as 19% of the relatives without CD-autoantibodies and none of the controls were seropositive for ASCA
IgA, ASCA IgG, or both. In addition, anti-I2 and anti-OmpW positivity was more common among the
autoantibody-negative relatives than controls (61% and 40% vs. 31% and 24%, respectively; Figure 1).
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p = 0.001; absorbance for anti-I2 0.93 vs. 0.71, p = 0.320 and for anti-OmpW 1.00 vs. 0.81, p = 0.022, 
respectively). In contrast to the autoantibody-negative group, anti-OmpW levels were also 
significantly higher than in the controls (absorbance 0.79, p = 0.043). 
Adjusting for age and gender or exclusion of children from the comparisons did not affect the 
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medians were significantly lower in children than in adults (ASCA IgA 6.30 vs. 9.64 U/mL, p < 0.001; 
ASCA IgG 7.13 vs. 9.18 U/mL, p = 0.070; absorbance for anti-I2 0.34 vs. 0.79, p < 0.001 and for anti-
OmpW 0.54 vs. 0.87, p < 0.001, respectively). 
Seropositivity to anti-I2 and anti-OmpW was significantly more frequent between relatives in 
the same family than between different families (p < 0.001 for anti-I2 and p = 0.001 for anti-OmpW, 
respectively). In ASCA, this was observed only when autoantibody-positive relatives were also 
included in the analysis (p = 0.007). 
There were no significant differences in the distribution of seropositivity across microbial 
markers when the relatives were categorized according to their HLA haplotypes (Table 2). 
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Pseudomonas fluorescens-associated sequence (anti-I2 ti i ) nd Bacteroides caccae TonB-linked outer
membrane protein (anti-OmpW an ibodies) among autoantibody-negative relatives of eliac disease
(CD) patients, CD patients (at diagnosis and on a GFD) nd controls.
The median levels of ASCA IgA, ASCA IgG and anti-I2 were also significantly higher in the
autoantibody-neg tiv r latives than those in the control group (Figure 2a–c), whereas anti-OmpW
was higher onl i un reated and tre ted CD pa ients (Figure 2d). ASCA IgG was higher in both
untre ted and treated CD pati nts and anti-I2/OmpW in untreat d patients when compared with
autoantibody-negative relatives (Figure 2b–d).
Altogether, 46 out of the 49 a toantibody-positive relatives had HLA-DQ2 haplotype,
DQ8 haplotype, o both. As many as 86% of them showed s roreactivity to at least one microbial
marker compared t 73% of the CD antibody-negative r latives, and the median levels of the microbi l
antibodies were also higher (ASCA IgA 11.1 vs. 8.90 U/mL, p = 0.019; ASCA IgG 12.8 vs. 8.37 U/mL,
p = 0.001; ab orbance f r anti-I2 0.93 vs. 0.71, p = 0.32 and for anti-OmpW 1.00 vs. 0 1, p = 0.022,
respectively). In c ntrast to the autoantibody-negative group, anti-OmpW levels were also significantly
high r than in the controls (absorbance 0.79, p = 0.043).
Adjusting for age and gend r r exclusion of children from the comparisons did not affect the
results of the prevalence of seropositivity nor median levels of the microbial markers, although the
medians were signific ntly lower in children than in adults (ASCA IgA 6.30 vs. 9.64 U/mL, p < 0.001;
ASCA IgG 7.13 v . 9.18 U/mL, p = 0.070; absorb ce for anti-I2 0.34 vs. 0.79, p < 0.001 and for
anti-OmpW 0.54 vs. 0 87, p < 0.001, respectively).
Seropositivity to anti-I2 and anti-OmpW was significantly more frequent between relatives in
the same family han between different families (p < 0.001 for anti-I2 and p = 0.001 for anti-OmpW,
respectively). In ASCA, this was observed only when autoantibody-positive relatives were also
included in the analysis (p = 0.007).
There were no significant differences in the distribution of seropositivity across microbial markers
when the r latives were categorized according to their HLA haplotypes (Table 2).
There was a weak, positive correlati n between the values of tTGab and ASCA IgA (r = 0.31,
p < 0.001), whereas correlation coefficients between the other microbial markers and tTGab or EmA
were <0.3.
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% % % %
ASCA IgA 11.2 10.4 12.5 10.1
ASCA IgG 12.9 13.4 0 14.6
Anti-I2 58.4 61.2 75.0 66.3
Anti-OmpW 39.5 35.8 25.0 43.8
ASCA, Anti-Saccharomyces cerevisiae antibodies; anti-I2, antibodies to Pseudomonas fluorescens-associated sequence;
anti-OmpW, antibodies to Bacteroides Caccae TonB-linked outer membrane protein; DQ2, HLA-DQA1*05-DQB1*02 (DQ2.5)
or HLA-DQ 1*02-DQB1*02 (DQ2.2); DQ8, HLA-DQA1*03-DQB1*0302. There were n statistically ignifica t differences
between the groups in the distribution of seropositivity.
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4. Discussion
The main finding of the present study was increased seroreactivity to microbial markers in the
relatives of CD patients compared with controls even after the exclusion of CD autoantibody-positive
individuals. This was observed particularly with ASCA and anti-I2, the median levels of which were
also significantly higher than levels in the controls, although they were lower than in CD patients.
To the best of our knowledge, the only study to report on this issue so far was a conducted by Da Silva et
al., who investigated seropositivity to ASCA in relatives of CD patients [28]. They divided 76 relatives
into EmA/tTGab negative and positive groups, while 57 individuals with negative CD autoantibodies
and no family risk served as controls. Partly in contrast to us, there was a significantly higher frequency
of positivity to ASCA IgA/G only in autoantibody-positive relatives compared with the controls [28].
This discrepancy may, at least in part, be explained by the smaller number of participants since there
was a trend toward overrepresentation of ASCA, also among the CD autoantibody-negative relatives.
There may also have been methodological differences, as the authors did not report the kits used for
the ASCA measurements.
Owing to the high specificity of tTGab and EmA [23], most of the autoantibody-positive relatives
were likely CD patients. Therefore, their increased seroreactivity to microbial markers is logically in
line with that observed in already-diagnosed CD. By contrast, the increased frequency of seroreactivity
to a part of the microbial markers in the autoantibody-negative relatives is not as easily explained.
It is to be noted that Setty and colleagues [29] previously reported that tTGab-negative relatives of
CD patients had signs of intestinal epithelial stress, demonstrated by ultrastructural alterations of
microvilli, and increased expression of heat shock proteins and interleukin-15 along with elevated
expression of activating NK receptors on intraepithelial cytotoxic T cells. Thus, even in the absence of
CD autoantibodies or characteristic histological damage to the intestine, at least some of the relatives
appeared to display proinflammatory responses reminiscent of CD. This raises the question of whether
the observed abnormal microbial antibody production could also be implicated in this process.
Setty et al. also speculated about a possible genetic predisposition to epithelial stress [29] and
suggested a possible HLA and other as yet-unidentified genetic associations. We observed no significant
association between the distribution of ASCA, anti-I2 and anti-OmpW positivity and the CD-related
HLA haplotypes, suggesting that at least HLA genetics does not markedly affect the serological
response. In line with this, HLA DQ2/8 are not overexpressed in inflammatory bowel disease (IBD)
patients [30] who also may have increased seropositivity to microbial markers [16,17]. Genetics may
still play a role in microbial antibody production in intestinal diseases, as demonstrated by two studies
comparing levels of microbial antibodies between monozygous and dizygous twin pairs with IBD.
Amcoff et al. reported that the differences in the anti-I2 antibody levels were smaller within than
between monozygous twin pairs, even if only one of them had IBD [31]. However, this was not
seen in dizygous twins with one suffering from IBD and the other being healthy and having partly
discordant genetics, supporting the role of genetic factors [31]. By contrast, similar ASCA levels were
observed only in a subgroup of monozygous twins both having IBD [31,32]. Bearing this in mind, it is
interesting that we found stronger associations of anti-I2 positivity between the relatives from the same
family than between the families, whereas with ASCA this was seen only when autoantibody-positive
relatives were included in the analysis. Taken together, it seems that both genetic and environmental
factors have a role in the antibody production, with this varying depending on the microbial marker,
but further studies are needed.
Environmental factors including gluten intake [33,34] and infections in early life [35–37] have also
been associated with increased CD risk. Other suggested, although controversial [38,39], risk factors
include bacterial infections and frequent use of antibiotics [40,41]. Interestingly, the incidence has been
reported to vary depending on socioeconomic circumstances [10], leading to the hypothesis that slight
microbial exposure increases CD risk by driving immune reactions toward autoantigens and dietary
components [42]. Close relatives usually share the living milieu and may, thus, experience similar
environmental modulatory effects on the microbiota and immune system that, in addition to genetics,
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could give rise to parallel responses to microbial antigens. It remains unclear, however, which external
factors drive these responses and whether the microbial markers have a causal role [43]. It is likely that
a complex interaction between multiple factors, such as dysregulation of the immune system, changes
in the epithelial barrier, and dysbiosis causes the loss of tolerance to microbial antigens [13,44–46].
In addition, a very recent study showed that Pseudomonas fluorescens peptides mimic gluten epitopes
and activate gliadin-reactive T cells, with this cross-reactivity possibly contributing to the onset of
CD [47].
We previously found most of the potential CD patients to already exhibit the microbial markers
before the development of villous damage or autoantibodies [21], reflecting the situation in the relatives
in the present study. Interestingly, Torres and colleagues recently showed that ASCA also predicts
forthcoming Crohn’s disease up to five years before the diagnosis [48]. More studies are needed to
determine the role of these markers in early development of CD and whether they could be utilized to
predict the disease in at-risk groups.
The main strengths of our study include the large and well-defined cohort of relatives of CD
patients who underwent systematic screening for CD-associated HLA and autoantibodies and the
representative control groups. As a weakness, however, large differences between the group sizes could
have influenced the results. Furthermore, only the groups with relatives contained pediatric subjects,
although the results remained unchanged after excluding children from the analyses. Genetic data
of the non-HLA alleles were also lacking, which could be an even more significant limitation among
relatives with a less marked HLA predisposition to CD. Since we did not have detailed information on
the health condition of the relatives, and the histological status of their intestines remains unknown,
it is possible that some of them had unreported CD or another disease affecting the results. Furthermore,
dietary data of the relatives was lacking, and it is possible that cross-reactions between food antigens
influenced the microbial antibody levels. ASCA is known to cross-react with other yeast strains [49],
and the lack of correlation between ASCA antibodies and Saccharomyces cerevisiae DNA on intestinal
mucosa [50] indicates the possibility of some yet-unidentified cross-reactive antigens. In accord with
our previous study [51], for currently unclear reasons, ASCA levels were generally higher in the
IgG class than the IgA class. By contrast, IgA class ASCA seems to be more consistently elevated
in IBD [48,52]. Which of these two antibody classes is the more useful marker in CD would be an
interesting subject for further research. The median duration of GFD in the CD group was only one
year, which may have biased the serological results, as histological and serological recovery often
take longer despite a strict diet [53]. Finally, a few adults here had surprisingly high anti-OmpW
values compared with our previous studies. Although we still believe that the used cutoff was valid,
we recommend that it be confirmed in other populations.
In conclusion, we found increased seroreactivity to serum microbial markers, particularly ASCA
and anti-I2, in relatives of CD patients even in the absence of the disease-specific autoantibodies or
other signs of active CD. This observation was not explained by the presence or absence of predisposing
HLA haplotypes, thereby suggesting the role of other genetic and environmental factors.
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